Healthcare / BiotechnologyTaiwan
$22.35
+1.65 (+7.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-600.6M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-26.4%
↓Gross Margin
22.8%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+118.5%
FCF CAGR
—
FCF margin
-11916.3%
FCF / Net income
1.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.5M · net income $-436.5M · FCF $-654.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.5M | $5.5M | $333000.00 | $90000.00 | $526000.00 |
| Net Income | $-436.5M | $-436.5M | $-315.5M | $-688.0M | $-274.3M |
| EBITDA | $-407.3M | $-407.3M | $-306.1M | $-682.5M | $-270.2M |
| EPS | — | — | -2.70 | -6.84 | -3.85 |
| Gross Margin | 22.8% | 22.8% | 6.6% | 100.0% | 100.0% |
| Operating Margin | -8250.9% | -8250.9% | -103539.0% | -771250.0% | -41506.8% |
| Net Margin | -7949.9% | -7949.9% | -94735.7% | -764468.9% | -52143.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 |
| Current Ratio | 27.33 | 27.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-654.2M | $-654.2M | $-359.2M | $-600.6M | $-173.1M |
| Returns | |||||
| ROE | -26.4% | -26.4% | -15.3% | -39.6% | -30.0% |
| Valuation | |||||
| P/B | 1.80 | 1.80 | 1.80 | 1.68 | 3.16 |
| Growth & Yield | |||||
| Revenue Growth | 1548.6% | 1548.6% | 270.0% | -82.9% | — |
| EPS Growth | — | — | 60.5% | -77.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.70 → n/d
Residual
-5.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.